Parameter | Method | Sample Type | Significance | |
---|---|---|---|---|
1 |
BRCA 1&2 |
PCR In- house |
Blood |
Prediction of inherited mutation in BRCA1/2 genes that may predict breast and ovarian cancer |
2 |
BCR-ABL Quantitation (IC in international format) |
Real time PCR |
Blood/ Bone marrow |
Quantification BCR-ABL fusion transcript b2a2,b2a3,b3a3,1a2,e1a3,e19a2,e19a3 against the reference gene Abl1. |
3 |
BCR-AB-7 translocate |
Real time PCR |
Blood/ Bone marrow |
Detection of breakpoints and mRNA splice variants for the 7 translocations |
4 |
BCR-ABL 28 translocate and +145 breakpoints and splice variants |
Real time PCR |
Blood/ Bone marrow |
Qualitative detection for 28 leukemia causing chromosomal translocations including more than 145 breakpoints plus associated mRNA splice variants. Furthermore, it detects new breakpoints and mRNA splice variants for the 28 translocations |
5 |
PML-RARA mutation in AML/APL patients |
Real time PCR |
Blood/ Bone marrow |
Diagnosis of acute promyelocytic leukemia (APL) / residual or recurrent APL /Monitoring the level of promyelocytic leukemia/retinoic acid receptor alpha (PML/RARA) in APL patients |
6 |
Imatinib Resistant mutation analysis in CML |
Real time PCR |
Blood |
Identify the pattern of mutations, so that second line tyrosine kinase inhibitors’ response may be studied with respect to these mutations and new drugs can be designed concentrating on the most common mutations. |
7 |
Microsatellite instability testing in colorectal cancer |
Real Time PCR |
Tissue/ Blood |
Microsatellite instability (MSI) is a molecular hallmark for certain colorectal cancers (CRCs) in which short tandem repeats are prone to mutations. |
8 |
Renal cell Carcinoma (RCC) |
PCR In- house |
Blood |
Confirmation of four major Autosomal dominantly inherited pathogenic germ line leading to RCC |
9 |
Lung cancer -EGFR (18,19,20,21 exon mutation) |
PCR In- house |
Blood |
Overexpression and oncogenic mutations that constitutively activate the TK domain of EGFR have been found in various solid tumors. The test helps in detection of mutation that leads to lung cancer |
10 |
Colon Cancer KRAS (codon 12, 13 mutation) |
PCR In- house |
Blood |
KRAS mutations have been commonly found in several types of human malignancies, such as metastatic colon cancer (mCRC), lung adenocarcinoma and thyroid cancer. The most common mutations are found in codons 12 and 13 of KRAS. |
11 |
Colorectal Cancer KRAS(exon 4), NRAS (exon 2, 3) |
PCR In- house |
Blood |
Detection of KRAS, NRAS mutations will help in Treatment decision-making in colorectal cancer |
12 |
Bone marrow disorder (JAK 2 mutation) |
PCR In- house |
Blood |
Mutations in JAK2 that are associated with bone marrow disorders caused by the production of too many blood cells |
13 |
Multiple endocrine neoplasia type 1 (MEN1) |
PCR In- house |
Blood
|
Multiple endocrine neoplasia (MEN1) is an autosomal dominant syndrome that leads to tumor development in parathyroid, pancreatic and pituitary glands. Genetic analysis will help in early treatment. |
14 |
BRAFV600E mutation |
PCR-Hybridization |
Blood |
Ultra-sensitive detection of BRAFV600E mutation |
15 |
BRAF mutation |
PCR-Hybridization |
Blood |
Ultra-sensitive detection of 9 BRAF mutations in codons 600 and 601 |
16 |
EGFR mutations (1 8/1 9/20/21) |
PCR-Hybridization |
Blood |
Ultra-sensitive detection of 30 EGFR mutations in exons 1 8/1 9/20/21 |
17 |
KRAS mutations |
PCR-Hybridization |
Blood |
Ultra-sensitive detection of 1 0 KRAS mutations in codons 12 and 13 |
18 |
KRAS-BRAF |
PCR-Hybridization |
Blood |
Ultra-sensitive detection of 1 0 KRAS mutations in codons 1 2/1 3 and BRAFV600E mutation |
19 |
KRAS XL |
PCR-Hybridization |
Blood |
Ultra-sensitive detection of 29 KRAS mutations in codons 1 2/1 3/59/60/61/1 1 7/1 46 |
20 |
NRAS XL |
PCR-Hybridization |
Blood |
Ultra-sensitive detection of 22 NBAS mutations in codons 1 2/1 3/59/60/61 /146 |